IDEXX Historical Balance Sheet

0J8P Stock

434.17 3.78 0.86%

Trend analysis of IDEXX Laboratories balance sheet accounts such as Other Current Liab of 391 M, Total Current Liabilities of 999.1 M or Total Stockholder Equity of 1.6 B provides information on IDEXX Laboratories' total assets, liabilities, and equity, which is the actual value of IDEXX Laboratories to its prevalent stockholders. By breaking down trends over time using IDEXX Laboratories balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining IDEXX Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether IDEXX Laboratories is a good buy for the upcoming year.

IDEXX Laboratories Inventory

399.3 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

About IDEXX Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of IDEXX Laboratories at a specified time, usually calculated after every quarter, six months, or one year. IDEXX Laboratories Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of IDEXX Laboratories and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which IDEXX currently owns. An asset can also be divided into two categories, current and non-current.

IDEXX Laboratories Balance Sheet Chart

At this time, IDEXX Laboratories' Cash is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 1.9 B in 2024, despite the fact that Other Stockholder Equity is likely to grow to (2.8 B).

Total Assets Other Current Liab Property Plant And Equipment Net Retained Earnings Accounts Payable Non Current Assets Total

Total Assets

Total assets refers to the total amount of IDEXX Laboratories assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in IDEXX Laboratories books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Accounts Payable

An accounting item on the balance sheet that represents IDEXX Laboratories obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of IDEXX Laboratories are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Most accounts from IDEXX Laboratories' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.At this time, IDEXX Laboratories' Cash is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 1.9 B in 2024, despite the fact that Other Stockholder Equity is likely to grow to (2.8 B).

	2021	2022	2023	2024 (projected)
Other Current Liabilities	396.4M	364.7M	372.4M	391.0M
Total Assets	2.4B	2.7B	3.3B	3.4B

Other Current Liab Total Assets

IDEXX Laboratories balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Short Term Debt	Common Stock	Short Term Investments	Current Deferred Revenue
Total Assets		0.95	0.75	0.73	0.99	0.49	0.91	0.95	0.63	0.98	0.76	0.48	0.98	-0.32	0.97	0.47	-0.92	0.82	0.96	0.77	0.68	0.69	0.14	0.54	0.88	0.6
Other Current Liab	0.95		0.71	0.59	0.95	0.57	0.82	0.97	0.46	0.96	0.85	0.33	0.96	-0.41	0.9	0.46	-0.86	0.86	0.87	0.88	0.69	0.71	0.1	0.59	0.87	0.75
Total Current Liabilities	0.75	0.71		0.19	0.72	0.86	0.52	0.77	0.27	0.69	0.43	0.48	0.69	-0.28	0.76	0.78	-0.65	0.92	0.78	0.73	0.55	0.94	0.75	0.67	0.77	0.56
Total Stockholder Equity	0.73	0.59	0.19		0.71	-0.22	0.89	0.59	0.75	0.72	0.6	0.33	0.73	0.05	0.74	-0.01	-0.75	0.2	0.69	0.19	0.57	0.03	-0.37	0.14	0.51	0.09
Property Plant And Equipment Net	0.99	0.95	0.72	0.71		0.49	0.9	0.95	0.59	0.99	0.78	0.41	0.98	-0.37	0.96	0.41	-0.91	0.81	0.93	0.79	0.63	0.68	0.09	0.51	0.88	0.65
Net Debt	0.49	0.57	0.86	-0.22	0.49		0.17	0.61	-0.14	0.47	0.31	0.22	0.48	-0.54	0.48	0.65	-0.35	0.89	0.48	0.79	0.26	0.95	0.74	0.51	0.55	0.64
Retained Earnings	0.91	0.82	0.52	0.89	0.9	0.17		0.84	0.67	0.92	0.76	0.3	0.92	-0.19	0.93	0.27	-0.97	0.55	0.83	0.5	0.72	0.38	-0.08	0.33	0.7	0.42
Accounts Payable	0.95	0.97	0.77	0.59	0.95	0.61	0.84		0.4	0.97	0.82	0.3	0.97	-0.43	0.93	0.46	-0.89	0.86	0.87	0.83	0.71	0.73	0.18	0.53	0.85	0.69
Cash	0.63	0.46	0.27	0.75	0.59	-0.14	0.67	0.4		0.52	0.25	0.76	0.53	0.18	0.56	0.3	-0.55	0.27	0.73	0.23	0.32	0.19	-0.14	0.32	0.55	0.14
Non Current Assets Total	0.98	0.96	0.69	0.72	0.99	0.47	0.92	0.97	0.52		0.84	0.31	1.0	-0.37	0.96	0.39	-0.94	0.79	0.89	0.78	0.71	0.64	0.06	0.5	0.85	0.65
Non Currrent Assets Other	0.76	0.85	0.43	0.6	0.78	0.31	0.76	0.82	0.25	0.84		-0.03	0.84	-0.32	0.75	0.12	-0.77	0.58	0.6	0.64	0.67	0.39	-0.14	0.36	0.66	0.57
Cash And Short Term Investments	0.48	0.33	0.48	0.33	0.41	0.22	0.3	0.3	0.76	0.31	-0.03		0.33	0.08	0.39	0.5	-0.23	0.41	0.7	0.31	0.09	0.47	0.3	0.39	0.5	0.04
Net Receivables	0.98	0.96	0.69	0.73	0.98	0.48	0.92	0.97	0.53	1.0	0.84	0.33		-0.41	0.96	0.37	-0.93	0.8	0.9	0.78	0.68	0.65	0.06	0.47	0.84	0.63
Common Stock Shares Outstanding	-0.32	-0.41	-0.28	0.05	-0.37	-0.54	-0.19	-0.43	0.18	-0.37	-0.32	0.08	-0.41		-0.27	-0.05	0.3	-0.5	-0.22	-0.63	0.11	-0.48	-0.04	0.2	-0.11	-0.55
Inventory	0.97	0.9	0.76	0.74	0.96	0.48	0.93	0.93	0.56	0.96	0.75	0.39	0.96	-0.27		0.46	-0.93	0.77	0.92	0.68	0.75	0.66	0.2	0.5	0.82	0.52
Other Current Assets	0.47	0.46	0.78	-0.01	0.41	0.65	0.27	0.46	0.3	0.39	0.12	0.5	0.37	-0.05	0.46		-0.43	0.69	0.56	0.52	0.56	0.74	0.74	0.76	0.56	0.52
Other Stockholder Equity	-0.92	-0.86	-0.65	-0.75	-0.91	-0.35	-0.97	-0.89	-0.55	-0.94	-0.77	-0.23	-0.93	0.3	-0.93	-0.43		-0.68	-0.82	-0.62	-0.76	-0.53	-0.09	-0.42	-0.74	-0.58
Total Liab	0.82	0.86	0.92	0.2	0.81	0.89	0.55	0.86	0.27	0.79	0.58	0.41	0.8	-0.5	0.77	0.69	-0.68		0.8	0.94	0.5	0.97	0.52	0.65	0.83	0.78
Total Current Assets	0.96	0.87	0.78	0.69	0.93	0.48	0.83	0.87	0.73	0.89	0.6	0.7	0.9	-0.22	0.92	0.56	-0.82	0.8		0.71	0.6	0.72	0.25	0.56	0.86	0.48
Non Current Liabilities Total	0.77	0.88	0.73	0.19	0.79	0.79	0.5	0.83	0.23	0.78	0.64	0.31	0.78	-0.63	0.68	0.52	-0.62	0.94	0.71		0.39	0.86	0.26	0.55	0.77	0.87
Intangible Assets	0.68	0.69	0.55	0.57	0.63	0.26	0.72	0.71	0.32	0.71	0.67	0.09	0.68	0.11	0.75	0.56	-0.76	0.5	0.6	0.39		0.36	0.19	0.64	0.62	0.41
Short Long Term Debt Total	0.69	0.71	0.94	0.03	0.68	0.95	0.38	0.73	0.19	0.64	0.39	0.47	0.65	-0.48	0.66	0.74	-0.53	0.97	0.72	0.86	0.36		0.69	0.61	0.73	0.68
Short Term Debt	0.14	0.1	0.75	-0.37	0.09	0.74	-0.08	0.18	-0.14	0.06	-0.14	0.3	0.06	-0.04	0.2	0.74	-0.09	0.52	0.25	0.26	0.19	0.69		0.48	0.28	0.19
Common Stock	0.54	0.59	0.67	0.14	0.51	0.51	0.33	0.53	0.32	0.5	0.36	0.39	0.47	0.2	0.5	0.76	-0.42	0.65	0.56	0.55	0.64	0.61	0.48		0.8	0.61
Short Term Investments	0.88	0.87	0.77	0.51	0.88	0.55	0.7	0.85	0.55	0.85	0.66	0.5	0.84	-0.11	0.82	0.56	-0.74	0.83	0.86	0.77	0.62	0.73	0.28	0.8		0.68
Current Deferred Revenue	0.6	0.75	0.56	0.09	0.65	0.64	0.42	0.69	0.14	0.65	0.57	0.04	0.63	-0.55	0.52	0.52	-0.58	0.78	0.48	0.87	0.41	0.68	0.19	0.61	0.68

Click cells to compare fundamentals

IDEXX Laboratories Account Relationship Matchups

IDEXX Laboratories balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Other Current Liab	276.5M	355.2M	396.4M	364.7M	372.4M	391.0M
Total Current Liabilities	725.3M	582.8M	763.6M	1.2B	951.5M	999.1M
Total Stockholder Equity	177.5M	632.1M	690.0M	608.7M	1.5B	1.6B
Property Plant And Equipment Net	533.8M	555.2M	587.7M	649.5M	817.7M	858.6M
Net Debt	897.3M	524.6M	779.2M	1.2B	613.4M	644.1M
Retained Earnings	1.6B	2.2B	2.9B	3.6B	4.4B	4.7B
Accounts Payable	72.2M	74.6M	116.1M	110.2M	110.6M	116.2M
Cash	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Non Current Assets Total	1.2B	1.2B	1.5B	1.6B	1.8B	1.9B
Non Currrent Assets Other	299.0M	337.2M	397.4M	425.6M	333.0M	349.6M
Cash And Short Term Investments	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Net Receivables	307.5M	374.7M	425.6M	490.9M	529.5M	556.0M
Common Stock Shares Outstanding	87.5M	86.7M	86.6M	84.6M	84.0M	94.9M
Liabilities And Stockholders Equity	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Inventory	195.0M	209.9M	269.0M	367.8M	380.3M	399.3M
Other Current Assets	86.8M	94.2M	116.6M	130.2M	131.5M	75.1M
Other Stockholder Equity	(1.4B)	(1.5B)	(2.2B)	(2.9B)	(2.9B)	(2.8B)
Total Liab	1.7B	1.7B	1.7B	2.1B	1.8B	1.9B
Total Current Assets	679.6M	1.1B	955.7M	1.1B	1.5B	1.6B
Non Current Liabilities Total	929.3M	1.1B	983.6M	902.2M	823.8M	865.0M
Intangible Assets	58.5M	52.5M	99.0M	97.7M	84.5M	66.7M
Short Long Term Debt Total	987.7M	908.5M	923.7M	1.3B	1.1B	1.1B
Short Term Debt	304.0M	67.7M	168.4M	674.4M	344.8M	212.2M
Accumulated Other Comprehensive Income	(46.2M)	(53.6M)	(53.5M)	(77.8M)	(71.2M)	(67.6M)
Common Stock	10.6M	10.6M	10.7M	10.7M	10.8M	9.2M
Current Deferred Revenue	41.5M	42.6M	40.0M	37.9M	37.2M	25.0M
Good Will	239.7M	243.3M	359.3M	361.8M	366.0M	218.6M
Other Assets	240.2M	289.6M	325.2M	1.0	1.15	1.09
Other Liab	162.9M	143.5M	121.0M	106.6M	95.9M	115.4M
Net Tangible Assets	(120.7M)	336.2M	231.6M	149.3M	171.7M	180.2M
Long Term Debt	499.6M	599.5M	858.5M	775.2M	891.5M	711.1M
Deferred Long Term Liab	108.6M	116.1M	122.4M	119.9M	137.9M	115.7M
Property Plant Equipment	614.5M	646.3M	692.8M	768.1M	883.3M	648.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for IDEXX Stock Analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC